Clinical Trial Detail

NCT ID NCT03824483
Title Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

CLL/SLL

chronic lymphocytic leukemia

Therapies

Obinutuzumab + Venetoclax + Zanubrutinib

Age Groups: adult senior

No variant requirements are available.